



# Biotech Daily

SPECIAL SUMMER CATCH-UP EDITION

Sunday, January 21, 2024

*The Summer Catch-Up Edition was compiled by Jamie Miller*

- \* THORNEY, TIGA TAKE 7% OF ENLITIC
- \* OPTHEA RECEIVES \$124m OPT-305 DEVELOPMENT FUNDING
- \* RADIOPHARM OPENS 2nd RAD204 NSCLC TRIAL SITE
- \* VITURA ENDS CODE4 CANVIEW SOFTWARE LICENCE
- \* PT PYRIDAM FARMA, PYFA TAKE 10% OF PROBIOTEC
- \* AUSTCO WINS \$1.2m WHITTLESEA CCTV CONTRACT
- \* FIREBRICK WITHDRAWS NASODINE TGA APPEAL
- \* MESOBLAST RETAIL RIGHTS RAISE \$5m; TOTAL: \$60m OF HOPED FOR \$90m
- \* CYNATA EXPECTS CYP-006TK RESULTS BY APRIL
- \* RECCE: 'R327 REDUCES 88% UTI E COLI, IN RATS'
- \* AUDEARA LOSES DIRECTOR DR ELAINE SAUNDERS
- \* ALGORAE: HL PHARMA MARIJUANA DISTRIBUTION AGREEMENT
- \* FIL (FIDELITY) BELOW 5% OF SOMNOMED
- \* OSTEOPORE TAKES \$1m ADVANCE OPPORTUNITIES FUND LOAN
- \* BVF PARTNERS DILUTED TO 24% OF SYNTARA
- \* RHYTHM LOSES DIRECTOR DR RACHEL DAVID
- \* NOVA EYE: US MACs CANCEL CANALOPLASTY MEDICARE CHANGES
- \* GENETIC SIGNATURES RAISES \$8m; \$7.9m TO GO
- \* ALTERITY 25% OPPOSE SPP, DIRECTOR PLACEMENT SHARES EGM
- \* HSBC INCREASES, DILUTED TO 10% IN SYNTARA
- \* VITROLIFE TO SELL MEMPHASYS FELIX IN CANADA, NEW ZEALAND

- \* **CARDIEX: 'ASX OPEN TO CONDITIONAL SUSPENSION LIFT AFTER \$8m RAISE'**
- \* **AROVELLA MAKES GMP VECTOR FOR ALA-101**
- \* **PHARMAUST FDA PRE-IND MONEPANTEL MND MEETING**
- \* **PYC: GOPOMELO, GOOGLE PARTNER FOR A.I.**
- \* **CSL APPOINTS SAMANTHA LEWIS DIRECTOR**
- \* **ANTISENSE FILES 'PERCHERON' NAME CHANGE**
- \* **PERENNIAL INCREASES, DILUTED TO 13% OF GENETIC SIGNATURES**
- \* **KARST PEAK INCREASES, DILUTED TO 11% OF SYNTARA**
- \* **ASIA UNION, FIL (FIDELITY) DILUTED IN GENETIC SIGNATURES**
- \* **L1 CAPITAL TAKES 16% OF ANTERIS**
- \* **SDI H1 REVENUE UP 3% TO \$52m**
- \* **IMMUTEP DOSES 1st EFTI UROTHELIAL CANCER PATIENT**
- \* **NOVA EYE TELLS ASX 'AWARE 4 HOURS BEFORE ANNOUNCEMENT'**
- \* **KARST PEAK REDUCE TO 10% OF SYNTARA**
- \* **CHIMERIC RAISES \$1m FROM LIND GLOBAL FUND**
- \* **RHYTHM REMOVAL OF CHAIR OTTO BUTTULA AS DIRECTOR EGM**
- \* **TELIX PLANS US NASDAQ LISTING**
- \* **CRYOSITE EQUAL REDUCTION CAPITAL RETURN**
- \* **VISIONEERING RAISES \$239k OF \$1.5m RIGHTS OFFER SHORTFALL**
- \* **TELIX 2023 REVENUE UP 236% TO \$503m**
- \* **NOVA EYE 6-MONTH US SALES UP 65% TO \$7.6m**
- \* **ZELIRA: \$2.9m OF \$5.1m NOTE FOR HOPE MARIJUANA AUTISM TRIAL**
- \* **GENETIC TECHNOLOGIES LOSES CFO CO SEC TONY DI PIETRO**
- \* **CANN GROUP APPOINTS TONY DI PIETRO CFO, CO-CO SEC**
- \* **SWINBURNE NEURODESK FOR BRAIN IMAGING DATA ANALYSIS**
- \* **THORNEY, TIGA DILUTED TO 48% OF VISIONEERING**
- \* **VITURA TO SELL NICTONE VAPES AS 'SMOKING CESSATION PRODUCTS'**
- \* **ADHERIUM: NUVOAIR TO BUY 1,000 HAILIE SENSORS**

- \* EMYRIA UNNAMED PSYCHIATRIST WINS TGA PRESCRIBER STATUS
- \* CHIMERIC RECEIVES \$7.4m FEDERAL R&D TAX INCENTIVE
- \* REGAL FUNDS TAKES 5% OF ALTERITY
- \* AVITA UNAUDITED REVENUE UP 46% TO \$50m
- \* COMPUMEDICS UNAUDITED H1 REVENUE UP 35% TO \$26m
- \* INVICTUS VGI PANCREATIC CANCER TRIAL APPROVED
- \* LUMOS SIGNS \$14.9m HOLOGIC IP DEVELOPMENT AGREEMENT
- \* IMRICOR ICMR APPROVED IN SAUDI ARABIA
- \* AVITA TO DISTRIBUTE STEDICAL PERMEADERM IN US
- \* TRAJAN: CLINISCIENCES TO SELL NEOTERYX IN EUROPE
- \* SANDHURST REDUCES TO 12% OF MACH 7
- \* FIREBRICK TO RELEASE 63m ASX ESCROW SHARES
- \* CHIMERIC OPENS PHASE Ib CHM0201 AML TRIAL
- \* EMYRIA RECEIVES \$2.5m FEDERAL R&D TAX INCENTIVE
- \* MEDLAB COMPLETES DR SEAN HALL SHARE SALE
- \* FIL (FIDELITY) REDUCES TO 9% OF IMMUTEP
- \* IMAGION LOSES 7-MONTH CEO ISAAC BRIGHT
- \* KIM BEAZLEY REPLACES ORTHOCELL DIRECTOR MATTHEW CALLAHAN
- \* RHINOMED 99% EGM VOTE TO DELIST FROM ASX
- \* MICRO-X LOSES FOUNDER PETER ROWLAND
- \* ADHERIUM LOSES CEO RICK LEGLEITER
- \* CLARITY LOSES DIRECTORS CHERYL MALEY, ROB THOMAS
- \* ECHO IQ APPOINTS KIMBER ROTHWELL CEO ON \$300k PA
- \* IMMURON RECORD H1 SALES UP 304% TO \$2.4m
- \* HERAMED, GPEX HERACARE PILOT PROGRAM
- \* MELODIOL UNAUDITED REVENUE UP 51% TO \$7.1m; \$215k PLACEMENT
- \* PHARMAUST: BERRY FOR PHASE II/III MONEPANTEL MND/AML TRIAL
- \* VICTORIA OPENS \$17m 'PANDEMIC PREPAREDNESS' GRANTS

- \* QUEENSLAND UNI H1A SPIDER VENOM PREVENTS HEART ATTACK, IN MICE
- \* WEHI FINDS 'LIKELY BREAST CANCER CELLS-OF-ORIGIN'
- \* IMMUNEXPRESS WINS SEPTICYTE SEPSIS TEST TGA APPROVAL
- \* AMPLIA DOSES 1st PHASE IIa NARMAFOTINIB PANCREATIC CANCER PATIENT
- \* PERENNIAL REDUCES TO 14% OF LUMOS
- \* LEAH PIERIS REPLACES ALGORAE CO SEC MADHUKAR BHALLA
- \* HERAMED LOSES DIRECTOR EMILY SLADE
- \* VICTORIA \$500k FOR ST VINCENT'S CELLULAR LABORATORY
- \* CHIMERIC PLACES \$3.2m OF \$5.5m SHORTFALL; TOTAL RAISED \$7.7m
- \* MEMPHASYS RIGHTS RAISE \$2.13m; TOTAL \$4.23m
- \* AMPLIA: FDA OKAYS NARMAFOTINIB PANCREATIC CANCER TRIAL IND
- \* IMRICOR TO START CARDIAC ABLATION CATHETER TRIAL
- \* RECCE R327 'RESOLVES/CURES DFI BACTERIAL INFECTIONS'
- \* HERAMED RIGHTS ISSUE TO RAISE UP-TO \$1.3m
- \* BLINKLAB HOPES FOR \$8m TO LIST ON ASX FOR AUTISM DIAGNOSTIC
- \* CONTROL BIONICS PLACES \$1m SHORTFALL; TOTAL \$2.7m
- \* MESOBLAST: 'FDA REVASCOR HLHS RARE PAEDIATRIC DISEASE STATUS'
- \* IMUGENE DOSES 1st PHASE I VAXINIA COHORT 5 PATIENTS
- \* STARPHARMA: 'DEP-CABAZITAXEL CANCER DISEASE CONTROL'
- \* VISIONEERING NATURALVUE 'FURTHER REDUCES MYOPIA PROGRESSION'
- \* ISLAND DOSES THIRD ISLA-101 DENGUE FEVER COHORT
- \* MICROBA TO RELEASE 54.5m ESCROW SHARES
- \* ENLITIC TO RELEASE 3.9m CDIs, 4.5m SHARES FROM ASX ESCROW
- \* PHOENIX DILUTED TO 18.3% IN CONTROL BIONICS
- \* NIGHTINGALE DILUTED TO 12.5% OF CONTROL BIONICS
- \* PETER FORD DILUTED TO 11.5% OF CONTROL BIONICS
- \* PAINCHEK APPOINTS NATALIE CLIMO CO SEC

**The following articles appear in date order**

**Friday December 22, 2023, after the market closed**

**THORNEY, TIGA TAKE 7% OF ENLITIC**

[ENLITIC INC](#)

Melbourne's Thorney Technologies and Tiga Trading say they have become substantial in Enlitic with 6,235,250 shares (7.23%), buying 1,566,265 shares in the initial public offer at 83 cents a share (BD: Dec 19, 2023).

**Monday December 25, Tuesday December 26, 2023**

ASX closed for Christmas, Boxing Day.

**Wednesday December 27, 2023**

**OPTHEA RECEIVES \$124m OPT-305 DEVELOPMENT FUNDING**

[OPTHEA](#)

Opthea says Washington's Carlyle Group and an undisclosed co-investor have committed \$US85 million (\$A124 million) to develop OPT-302 for wet-aged macular degeneration.

**RADIOPHARM OPENS 2nd RAD204 NSCLC TRIAL SITE**

[RADIOPHARM THERANOSTICS](#)

Radiopharm says Perth's Hollywood Private Hospital will be the second site of its 21-patient, phase I trial of RAD204 for non-small cell-lung cancer (NSCLC).

**VITURA ENDS CODE4 CANVIEW SOFTWARE LICENCE**

[VITURA HEALTH](#)

Vitura says it won't extend its Code4 Cannabis Pty Ltd's software licence, used for its Canview platform, beyond August 10, 2024, due to "issues with their ... conduct".

**PT PYRIDAM FARMA, PYFA TAKE 10% OF PROBIOTEC**

[PROBIOTEC](#)

Jakarta's PT Pyridam Farma Tdk says it has become substantial in target Probiotec, acquiring 8,400,873 shares (10.33%) at \$3.00 a share (BD: Dec 22, 2023).

**AUSTCO WINS \$1.2m WHITTLESEA CCTV CONTRACT**

[AUSCTO HEALTHCARE](#)

Austco says it has a \$1.2 million contract with Melbourne's Whittlesea Community Hospital for its closed circuit television healthcare management and monitoring.

**FIREBRICK WITHDRAWS NASODINE TGA APPEAL**

[FIREBRICK PHARMA](#)

Firebrick says it has withdrawn its appeal against the Australian Therapeutic Goods Administration's decision not to approve its Nasodine nasal spray (BD: Mar 1, 2022).

**Thursday December 28, 2023**

**MESOBLAST RETAIL RIGHTS RAISE \$5m; TOTAL: \$60m OF HOPED FOR \$90m**  
[MESOBLAST](#)

Mesoblast says its retail rights raised \$5.3 million at 30 cents a share, taking the total raised to \$60.3 million of a hoped-for \$90 million (BD: Dec 5, 2023).

**CYNATA EXPECTS CYP-006TK RESULTS BY APRIL**  
[CYNATA THERAPEUTICS](#)

Cynata says it has begun analysing 10-week results from 16 of 30 patients in its phase I trial of CYP-006TK for diabetic foot ulcers and expects results by April, 2024.

**RECCE: 'R327 REDUCES 88% UTI E COLI, IN RATS'**  
[RECCE PHARMACEUTICALS](#)

Recce says a study of R327 at a 500mg/kg dose shows it reduces escherichia coli by 99 percent and urinary tract infection bacterial load in rats.

**AUDEARA LOSES DIRECTOR DR ELAINE SAUNDERS**  
[AUDEARA](#)

Audeara says non-executive director Dr Elaine Saunders has resigned, effective from December 31, 2023.

**ALGORAE: HL PHARMA MARIJUANA DISTRIBUTION AGREEMENT**  
[ALGORAE PHARMACEUTICALS](#)

Algorae says Melbourne's HL Pharma will import and store its marijuana products and distribute them to its research partners La Trobe University and Monash University.

**FIL (FIDELITY) BELOW 5% OF SOMNOMED**  
[SOMNOMED](#)

FIL Limited (Fidelity Investment) says it has ceased its substantial shareholding in Somnomed, selling 1,163,681 shares for between 42.25 cents to 60 cents a share.

**OSTEOPORE TAKES \$1m ADVANCE OPPORTUNITIES FUND LOAN**  
[OSTEOPORE](#)

Osteopore says it has borrowed \$1 million from Singapore's Advance Opportunities Fund, at up-to eight percent monthly interest, to fund its general working capital requirements.

**Friday December 29, 2023**

**BVF PARTNERS DILUTED TO 24% OF SYNTARA**  
[SYNTARA \(FORMERLY PHARMAXIS\)](#)

San Francisco's BVF Partners LP says its 201,488,850 shares in Syntara was diluted from 28.03 percent to 24.24 percent due to a capital raising (BD: Dec 19, 2023).

**RHYTHM LOSES DIRECTOR DR RACHEL DAVID**  
[RHYTHM BIOSCIENCES](#)

Rhythm says non-executive director Dr Rachel David has retired, effective from December 28, 2023, due to her "other corporate roles and responsibilities".

## **NOVA EYE: US MACs CANCEL CANALOPLASTY MEDICARE CHANGES**

### [NOVA EYE MEDICAL](#)

Nova Eye says all five US Medicare Administrative Contractors (MACs) have cancelled proposed canaloplasty coverage changes, with US sales to be unaffected.

In November, Nova Eye said five MACs had proposed to limit or deny coverage for several minimally invasive glaucoma surgery procedures (BD: Nov 14, 2023).

## **GENETIC SIGNATURES RAISES \$8m; \$7.9m TO GO**

### [GENETIC SIGNATURES](#)

Genetic Signatures says its placement at 37.0 cents a share raised about \$8 million, to be followed by a one-for-6.5 rights issue to raise up-to \$7.9 million.

In December, Genetic Signatures said it raised \$15.9 million through a \$7.96 million placement and a \$7.98 million fully-underwritten rights issue (BD: Dec 21, 2023).

## **ALTERITY 25% OPPOSE SPP, DIRECTOR PLACEMENT SHARES EGM**

### [ALTERITY THERAPEUTICS](#)

Alterity says its general meeting passed all resolutions but with up-to 25.44 percent against its share purchase plan and the issue of placement shares to directors.

The 25 million votes against the issue of shares amounts to about 1.6 percent of the shares on issue.

## **Monday January 1, 2024**

ASX closed for New Year's Day.

## **Tuesday January 2, 2024**

## **HSBC INCREASES, DILUTED TO 10% IN SYNTARA**

### [SYNTARA \(FORMERLY PHARMAXIS\)](#)

London's HSBC Holdings says it increased its substantial holding in Syntara to 85,391,307 shares, and been diluted to 11.72 percent due to a capital raise (BD: Dec 19, 2023).

## **VITROLIFE TO SELL MEMPHASYS FELIX IN CANADA, NEW ZEALAND**

### [MEMPHASYS](#)

Memphasys says Sweden's Vitrolife AB will sell its Felix sperm separation system for in-vitro fertilization in Canada and New Zealand for five years.

## **CARDIEX: 'ASX OPEN TO CONDITIONAL SUSPENSION LIFT AFTER \$8m RAISE'**

### [CARDIEX](#)

Cardiex says that following an \$8 million capital raise, the ASX has agreed to progress discussions in relation to lifting its voluntary suspension (BD: Oct 4, Dec 7, 2023).

## **AROVELLA MAKES GMP VECTOR FOR ALA-101**

### [AROVELLA THERAPEUTICS](#)

Arovella says it has good manufacturing practice (GMP)-grade lentiviral vector to be used in the production of its lead product ALA-101 for lymphomas and leukaemias.

## **PHARMAUST FDA PRE-IND MONEPANTEL MND MEETING**

### **[PHARMAUST](#)**

Pharmaust says it will have a pre-investigational new drug (IND) meeting with the US Food and Drug Administration on monepanTEL for motor neuron disease (MND).

## **PYC: GOPOMELO, GOOGLE PARTNER FOR A.I.**

### **[PYC THERAPEUTICS](#)**

PYC says it will pay \$10 million to develop an artificial intelligence-based drug development and discovery platform with Gopomelo Pte Ltd and Google Cloud. PYC said the companies would pay \$4.5 million for its data sets to execute the project, which would take 12 months, and it would own any intellectual property developed.

## **CSL APPOINTS SAMANTHA LEWIS DIRECTOR**

### **[CSL](#)**

In an Appendix 3X, Samantha Lewis says she was appointed as a non-executive director of CSL on January 1, 2024.

## **ANTISENSE FILES 'PERCHERON' NAME CHANGE**

### **[ANTISENSE THERAPEUTICS](#)**

Antisense says following shareholder approval, it has applied with the ASX to change its name to 'Percheron' and will trade under the ASX code 'PER'.

## **PERENNIAL INCREASES, DILUTED TO 13% OF GENETIC SIGNATURES**

### **[GENETIC SIGNATURES](#)**

Melbourne's Perennial Value Management says it has increased its Genetic Signatures holding to 20,894,990 shares, and been diluted to 12.67 percent due to a capital raise.

**Wednesday January 3, 2024**

## **KARST PEAK INCREASES, DILUTED TO 11% OF SYNTARA**

### **[SYNTARA \(FORMERLY PHARMAXIS\)](#)**

Hong Kong's Kast Peak Capital Ltd says it increased its holding in Syntara to 87,940,615 shares, which was diluted to 10.58 percent due to a capital raise (BD: Dec 21, 2023).

## **ASIA UNION, FIL (FIDELITY) DILUTED IN GENETIC SIGNATURES**

### **[GENETIC SIGNATURES](#)**

Sydney's Asia Union Investments Pty Ltd and Hong Kong's FIL Ltd (Fidelity Investment) say they have been diluted in Genetic Signatures after its recent capital raising.

Asia Union said it had reduced its holding to 37,584,516 shares (22.79%) and FIL said it had increased to 16,475,459 shares (9.99%).

## **L1 CAPITAL TAKES 16% OF ANTERIS**

### **[ANTERIS TECHNOLOGIES](#)**

Melbourne's L1 Capital Pty Ltd says it has increased its substantial shareholding in Anteris to 2,843,398 shares (15.96%), through the exercise of 330,000 options.



**Thursday January 4, 2024**

**SDI H1 REVENUE UP 3% TO \$52m**

[SDI \(FORMERLY SOUTHERN DENTAL INDUSTRIES\)](#)

SDI says that unaudited revenue for the six months to December 31, 2023 was up 3.2 percent to \$52.1 million compared to the previous corresponding period's \$50.5 million.

**IMMUTEP DOSES 1st EFTI UROTHELIAL CANCER PATIENT**

[IMMUTEP](#)

Immutep says it has dosed the first of up-to 30 patients in its phase I trial of eftilagimod alpha, or 'efti', with avelumab for the bladder cancer metastatic urothelial carcinoma.

**NOVA EYE TELLS ASX 'AWARE 4 HOURS BEFORE ANNOUNCEMENT'**

[NOVA EYE MEDICAL](#)

Nova Eye has told the ASX it became aware of the withdrawal of US Medicare changes at 6am (ACDT) on December 29, 2023, the day of the announcement.

**KARST PEAK REDUCE TO 10% OF SYNTARA**

[SYNTARA](#)

Hong Kong's Karst Peak Capital Ltd says it has reduced its holding in Syntara from 87,940,615 shares (10.58%) to 79,450,766 shares (9.56%).

**CHIMERIC RAISES \$1m FROM LIND GLOBAL FUND**

[CHIMERIC THERAPEUTICS](#)

Chimeric says it has raised \$1 million from New York's Lind Global Fund II, at 4.6 cents a share (BD: Jun 23, 2023).

**RHYTHM REMOVAL OF CHAIR OTTO BUTTULA AS DIRECTOR EGM**

[RHYTHM BIOSCIENCES](#)

Rhythm says an extraordinary general meeting will vote to remove chair Otto Buttula as a director, following a section 249D shareholder requisition (BD: Dec 15, 2023).

**Friday January 5, 2024**

**TELIX PLANS US NASDAQ LISTING**

[TELIX PHARMACEUTICALS](#)

Telix says it is considering an initial public offering of American depository shares on the Nasdaq and will remain listed on the ASX.

**CRYOSITE EQUAL REDUCTION CAPITAL RETURN**

[CRYOSITE](#)

Cryosite says it will conduct a reduction of capital through a capital return to shareholders at 5.0 cents a share, subject to shareholder approval.

**VISIONEERING RAISES \$239k OF \$1.5m RIGHTS OFFER SHORTFALL**

[VISIONEERING TECHNOLOGIES](#)

Visioneering says it has raised \$238,665 of a \$1.5 million shortfall, from its hoped-for \$3.9 million rights offer at 22 cents per Chess depository interest (BD: Nov 13, 2023).

**Monday January 8, 2023**

**TELIX 2023 REVENUE UP 236% TO \$503m**

[TELIX PHARMACEUTICALS](#)

Telex says unaudited revenue, primarily from sales of its Illucix prostate cancer imaging kit, for the year to December 31, 2023 was up 235.7 percent to \$502.5 million, Telex said the revenue, primarily from Illucix sales in the US for the three months to December 31, 2023, was up 11 percent on the prior period to \$148.1 million.

**NOVA EYE 6-MONTH US SALES UP 65% TO \$7.6m**

[NOVA EYE MEDICAL](#)

Nova Eye says US sales of its Itrack glaucoma surgery products were up 65 percent to \$US 5.1 million (\$A7.6 million) in the six months to December 31, 2023. Nova Eye said sales were “negatively impacted” by uncertainty reimbursement but the withdrawal of the proposed changes was expected to increase future sales.

**ZELIRA: \$2.9m OF \$5.1m NOTE FOR HOPE MARIJUANA AUTISM TRIAL**

[ZELIRA THERAPEUTICS](#)

Zelira says it has received the second tranche of \$US819,000 (\$1,217,000) from the Forman Trust and Mr Malik Majeed for its trial of Hope marijuana for autism.

**GENETIC TECHNOLOGIES LOSES CFO CO SEC TONY DI PIETRO**

[GENETIC TECHNOLOGIES](#)

Genetic Technologies says its chief financial officer and company secretary Tony Di Pietro has resigned, continuing in the roles until a replacement is found.

**CANN GROUP APPOINTS TONY DI PIETRO CFO, CO-CO SEC**

[CANN GROUP](#)

Cann says it has appointed Tony Di Pietro chief financial officer and joint company secretary, replacing Deborah Ambrosini, effective from April 8, 2024 (see above).

**Tuesday January 9, 2024**

**SWINBURNE NEURODESK FOR BRAIN IMAGING DATA ANALYSIS**

[SWINBURNE UNIVERSITY](#)

Swinburne University says it has developed the brain imaging data analysis platform, Neurodesk, with the University of Queensland and the University of Sydney. Swinburne said researchers could use Neurodesk to analyze data sets from magnetic resonance imaging, magneto-encephalography and electro-encephalogram at their own computers.

The University said with further funding researchers hoped to include other neuro-imaging methods and applications to “fast-track the process of diagnosis and treatment for brain related illnesses”.

**THORNEY, TIGA DILUTED TO 48% OF VISIONEERING**

[VISIONEERING TECHNOLOGIES](#)

Melbourne’s Thorney Investment Group and Tiga Trading say their holding of 25,209,833 shares in Visioneering were diluted from 49.15 percent to 48.13 percent (see above).

**VITURA TO SELL NICOTINE VAPES AS ‘SMOKING CESSATION PRODUCTS’**  
[VITURA HEALTH](#)

Vitura says it has added prescription-only “smoking cessation products” for patients who want to “quit smoking and reduce their nicotine dependency”.  
The company did not define “smoking cessation”.

**Wednesday January 10, 2024**

**ADHERIUM: NUVOAIR TO BUY 1,000 HAILIE SENSORS**  
[ADHERIUM](#)

Adherium says Boston’s Nuvoair will purchase a minimum of 1,000 of its Hailie inhaler sensors for monitoring asthma and chronic obstructive pulmonary disease.

**EMYRIA UNNAMED PSYCHIATRIST WINS TGA PRESCRIBER STATUS**  
[EMYRIA](#)

Emyria says its “specialist psychiatrist” has Australian Therapeutic Goods Administration authorized prescriber status, allowing the company to prescribe 3-4 methylene-dioxy-methamphetamine (MDMA).

**CHIMERIC RECEIVES \$7.4m FEDERAL R&D TAX INCENTIVE**  
[CHIMERIC THERAPEUTICS](#)

Chimeric says it has received \$7,357,688 from the Australian Taxation Office under the Federal Government’s Research and Development Tax Incentive program.

**REGAL FUNDS TAKES 5% OF ALTERITY**  
[ALTERITY THERAPEUTICS](#)

Sydney’s Regal Funds Management says it has become substantial in Alterity with 199,870,294 shares, or 5.24 percent.

**Thursday January 11, 2024**

**AVITA UNAUDITED REVENUE UP 46% TO \$50m**  
[AVITA MEDICAL](#)

Avita says revenue for the year to December 31, 2023, was up 46 percent to \$49.8 million, and expects 2024 revenue to be between \$78.5 million and \$84.5 million.

**COMPUMEDICS UNAUDITED H1 REVENUE UP 35% TO \$26m**  
[COMPUMEDICS](#)

Compumedics says unaudited revenue for the six months to December 31, 2023, was up 35 percent to \$26 million, and expects to report a profit for the period.

**INVICTUS VGI PANCREATIC CANCER TRIAL APPROVED**  
[VGI HEALTH TECHNOLOGY, INVICTUS BIOPHARMA HOLDINGS](#)

VGI says Invictus has ethics approval for an 80-patient, placebo-controlled, phase II trial of its transmucosal tocotrienols, or IVB003, for pancreatic cancer in Australia.  
VGI said the trial would dose patients three times daily with 120mg of IVB003, with a primary endpoint of progression free survival.

## **LUMOS SIGNS \$14.9m HOLOGIC IP DEVELOPMENT AGREEMENT**

### [LUMOS DIAGNOSTICS](#)

Lumos says Marlborough, Massachusetts' Hologic Inc will pay it \$US10 million (\$A14.9 million) to improve their women's health products and adapt it for use with its platform.

## **IMRICOR ICMR APPROVED IN SAUDI ARABIA**

### [IMRICOR](#)

Imricor says it has Saudi Food and Drug Authority marketing authorization for its interventional cardiac magnetic resonance (ICMR) imaging cardiac ablation products. Imricor said it expects first sales within six months.

## **AVITA TO DISTRIBUTE STEDICAL PERMEADERM IN US**

### [AVITA MEDICAL](#)

Avita says it has an agreement with San Diego's Stedical Scientific to exclusively commercialize its Permeaderm bio-synthetic wound treatment in the US.

## **TRAJAN: CLINISCIENCES TO SELL NEOTERYX IN EUROPE**

### [TRAJAN GROUP HOLDINGS](#)

Trajan says the Paris-based Clinisciences will distribute its Neoteryx micro-sampling products, Hemapen and Mitra, in France, Italy, Spain and Portugal.

In an email not announced to the ASX, Trajan said the devices could collect 'micro-sized' blood samples from patient fingertips at home, work, in a lab, or in a hospital.

## **SANDHURST REDUCES TO 12% OF MACH 7**

### [MACH 7 TECHNOLOGIES](#)

Melbourne's Sandhurst Trustees Ltd says it has decreased its substantial shareholding in Mach 7 from 31,608,994 shares (13.17%) to 28,372,672 shares (11.76%).

**Friday January 12, 2024**

## **FIREBRICK TO RELEASE 63m ASX ESCROW SHARES**

### [FIREBRICK PHARMA](#)

Firebrick says it will release 62,732,537 shares from ASX escrow on January 28, 2024, with 60,108,824 shares held by its directors, who had no intention of selling.

According to its most recent filing, following the release of the shares, the company will have 178,046,736 shares available for trading.

**Monday January 13, 2024**

## **CHIMERIC OPENS PHASE Ib CHM0201 AML TRIAL**

### [CHIMERIC THERAPEUTICS](#)

Chimeric says it has opened its up-to 20-patient, phase Ib trial of CHM0201 natural-killer cells with standard-of care for acute myeloid leukaemia (AML).

## **EMYRIA RECEIVES \$2.5m FEDERAL R&D TAX INCENTIVE**

### [EMYRIA](#)

Emyria says it has received \$2,527,316 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.

## **MEDLAB COMPLETES DR SEAN HALL SHARE SALE**

### [MEDLAB CLINICAL](#)

Medlab says it has completed the sale of 100 percent of its issued capital, its wholly owned subsidiary Medlab Pty Ltd and its intellectual property to director Dr Sean Hall.

## **FIL (FIDELITY) REDUCES TO 9% OF IMMUTEP**

### [IMMUTEP](#)

FIL Ltd (Fidelity Investments) says it has reduced its holding in Immutep to 105,180,649 shares (8.85%), selling shares from 31.32 cents to 35.50 cents each.

## **IMAGION LOSES 7-MONTH CEO ISAAC BRIGHT**

### [IMAGION BIOSYSTEMS](#)

Imagion says its seven months chief executive officer Dr Isaac Bright has resigned, to “pursue other opportunities”, with chair Bob Proulx appointed interim executive chair.

## **KIM BEAZLEY REPLACES ORTHOCELL DIRECTOR MATTHEW CALLAHAN**

### [ORTHOCELL](#)

Orthocell says it has appointed former Deputy Prime Minister and Labor Opposition Leader Kim Beazley as a non-executive director, replacing Matthew Callahan.

**Tuesday January 16, 2024**

## **RHINOMED 99% EGM VOTE TO DELIST FROM ASX**

### [RHINOMED](#)

Rhinomed says that 98.79 percent of its extraordinary general meeting voted to delist from the ASX (BD: Dec 11, 2023).

## **MICRO-X LOSES FOUNDER PETER ROWLAND**

### [MICRO-X](#)

In an Appendix 3Z Final Director’s Interest Notice, Micro-X founding managing-director Peter Rowland says he resigned on November 30, 2023.

## **ADHERIUM LOSES CEO RICK LEGLEITER**

### [ADHERIUM](#)

Adherium says chief executive officer Rick Legleiter has resigned “for family reasons”, effective in six months, with Lou Panaccio acting as executive chair.

## **CLARITY LOSES DIRECTORS CHERYL MALEY, ROB THOMAS**

### [CLARITY PHARMACEUTICALS](#)

Clarity says non-executive director Chery Maley has resigned, effective immediately, and independent director Rob Thomas will resign on August 23, 2024.

Clarity said Ms Maley had resigned to focus on her role as chief executive officer of Starpharma, and Mr Thomas would resign to focus on his role as Starpharma chair.

## **ECHO IQ APPOINTS KIMBER ROTHWELL CEO ON \$300k PA**

### [ECHO IQ](#)

Echo IQ says it has appointed Kimber Rothwell as its chief executive officer, on a base salary of \$300,000 a year, along with 2,250,000 performance rights and 3,000,000 options and effective from January 29, 2024.

## **IMMURON RECORD H1 SALES UP 304% TO \$2.4m**

### [IMMURON](#)

Immuron says sales for the six months to December 31, 2023 was up 303.6 percent to \$2,355,580, due to an increase in sales of its Travelan for travellers' diarrhoea.

## **HERAMED, GPEX HERACARE PILOT PROGRAM**

### [HERAMED](#)

Heramed says it will conduct a six-to-nine-month, 100-pregnancy pilot program of its Heracare platform with Adelaide's Gpex to show "the platform's clinical usability".

## **MELODIOL UNAUDITED REVENUE UP 51% TO \$7.1m; \$215k PLACEMENT**

### [MELODIOL GLOBAL HEALTH \(FORMERLY CRESO PHARMA\)](#)

Melodiol says unaudited revenue for the year to December 31, 2023 was up 51 percent to \$7.1 million, and it raised \$215,000 in a placement at 0.13 cents a share.

## **PHARMAUST: BERRY FOR PHASE II/III MONEPANTEL MND/AML TRIAL**

### [PHARMAUST](#)

Pharmaust says the Austin, Texas Berry Consultants will design its phase II/III study of monepantel for motor neuron disease (MND) and amyotrophic lateral sclerosis (AML).

**Wednesday January 17, 2024**

## **VICTORIA OPENS \$17m 'PANDEMIC PREPAREDNESS' GRANTS**

### [VICTORIA GOVERNMENT](#)

Victoria says it will provide \$17 million in grants to researchers developing novel therapeutics for pathogens "likely to be involved in ... future pandemics".

The Government said the Cumming Global Centre for Pandemic Therapeutics had awarded \$12 million to 22 teams, with \$5 million still available.

## **QUEENSLAND UNI HI1A SPIDER VENOM PREVENTS HEART ATTACK, IN MICE**

### [THE UNIVERSITY OF QUEENSLAND](#)

The University of Queensland says its spider venom-based molecule Hi1a protects cells from the damage caused by heart attack and stroke, in mice.

The University said Hi1a was "as effective at protecting the heart as the only cardio-protective drug to reach phase III trials", but that drug had side effects.

Lead researcher Prof Nathan Palpant said that "Hi1a only interacts with cells in the injured zone of the heart during an attack and doesn't bind to healthy regions of the heart, reducing the chance of side effects".

## **WEHI FINDS 'LIKELY BREAST CANCER CELLS-OF-ORIGIN'**

### [THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH](#)

The Walter and Eliza Hall Institute says it has found the likely 'cells-of-origin' which develop into breast cancers in high-risk women who carry a faulty BRCA2 gene.

The Institute said the research compared both carriers and non-carriers of the BRCA2 gene and found a subset of breast ductal cells in BRCA2 tissue called luminal progenitor cells which divided more quickly and were critical for the correct growth and function of tissue.

WEHI said researchers targeted these cells in preclinical BRCA2 models with the approved cancer drug everolimus and found that it "delayed the formation of tumors".

## **IMMUNEXPRESS WINS SEPTICYTE SEPSIS TEST TGA APPROVAL**

### [IMMUNEXPRESS PTY LTD](#)

Immunexpress says the Australian Therapeutic Goods Administration has granted its Septicyte Rapid one-hour, sepsis diagnostic test commercial approval.

In 2022, Immunexpress said it applied for TGA approval for its Septicyte Rapid test for distinguishing sepsis from system inflammation response syndrome, and it was already approved in the US and Europe (BD: Oct 5, 2022).

## **AMPLIA DOSES 1st PHASE IIa NARMAFOTINIB PANCREATIC CANCER PATIENT**

### [AMPLIA THERAPEUTICS](#)

Amplia says it has dosed the first of up-to 50 patients in its phase IIa trial of narmafotinib, formerly AMP945, with standard-of-care for pancreatic cancer.

## **PERENNIAL REDUCES TO 14% OF LUMOS**

### [LUMOS DIAGNOSTICS HOLDINGS](#)

Sydney's Perennial Value Management says it has reduced its holding in Lumos from 72,194,867 shares (15.00%) to 65,644,275 shares (13.64%).

## **LEAH PIERIS REPLACES ALGORAE CO SEC MADHUKAR BHALLA**

### [ALGORAE PHARMACEUTICALS](#)

Algorae says its company secretary Madhukar Bhalla has resigned and will be replaced by Automic Group's Leah Pieris, effective from January 17, 2024.

## **HERAMED LOSES DIRECTOR EMILY SLADE**

### [HERAMED](#)

Heramed says non-executive director Emily Slade has resigned, effective immediately.

**Thursday January 18, 2024**

## **VICTORIA \$500k FOR ST VINCENT'S CELLULAR LABORATORY**

### [VICTORIA GOVERNMENT](#)

The Victoria Government says it has contributed \$500,000 to a cellular laboratory at Melbourne's St Vincent's Hospital to further cancer research.

The Government said the laboratory would assist trials targeting blood cancer by increasing access to chimeric antigen receptor T(CAR-T) cells and T cell engagers.

## **CHIMERIC PLACES \$3.2m OF \$5.5m SHORTFALL; TOTAL RAISED \$7.7m**

### [CHIMERIC THERAPEUTICS](#)

Chimeric says it has placed \$3.2 million of its \$5.5 million entitlement offer shortfall at 2.8 cents a share, taking the total raised in the offer to about \$7.66 million.

Last year, Chimeric said its rights offer at 2.8 cents a share raised \$4.5 million of a hoped-for \$10 million, leaving a \$5.5 million shortfall (BD: Dec 7, 2023).

## **MEMPHASYS RIGHTS RAISE \$2.13m; TOTAL \$4.23m**

### [MEMPHASYS](#)

Memphasys says its two-for-nine rights offer at one cent a share had applications for 54,305,732 shares with a shortfall placed of 158,922,042 shares.

In December, Memphasys said a placement raised \$2.1 million and the rights offer was fully-underwritten by Canaccord Genuity Australia (BD: Dec 4, 2023).

**AMPLIA: FDA OKAYS NARMAFOTINIB PANCREATIC CANCER TRIAL IND**  
[AMPLIA THERAPEUTICS](#)

Amplia says the US Food and Drug Administration has approved its investigational new drug application for narmafotinib, formerly AMP945, for pancreatic cancer. Amplia said it would expand its up-to 50 patient, phase IIa clinical trial of its focal adhesion kinase (FAK) inhibitor, narmafotinib, in Australia and South Korea, to the US.

**IMRICOR TO START CARDIAC ABLATION CATHETER TRIAL**  
[IMRICOR MEDICAL SYSTEMS](#)

Imricor says it has approval for its up-to 91 patient study of its cardiac ablation catheter and irrigation pump products at the Baltimore, Maryland's Johns Hopkins Hospital. Imricor said the trial would study the safety and efficacy of atrial flutter ablation procedures using its Vision-MR cardiac ablation catheter and HAT500RF generator and irrigation pump, with an analysis after 76 patients had a seven-day follow-up.

**RECCE R327 'RESOLVES/CURES DFI BACTERIAL INFECTIONS'**  
[RECCE PHARMACEUTICALS](#)

Recce says a five-patient, phase I/II trial of R327 anti-infective gel met its primary endpoints of "resolving/curing bacterial infections in [diabetic foot infections]". Recce said patients were treated either daily or every second day, only one patient was escalated to systemic therapy due to several co-morbidities, and it would "look to expand clinical sites ... in the interest of accessing a greater patient population".

**HERAMED RIGHTS ISSUE TO RAISE UP-TO \$1.3m**  
[HERAMED](#)

Heramed says it hopes to raise up-to \$1.28 million in a one-for-five rights issue at 2.0 cents a share to fund commercialization of its Heracare pregnancy monitoring platform. Heramed said the rights issue had a record date of January 23, would open on January 29 and close on February 7, 2024.

**Friday January 19, 2024**

**BLINKLAB HOPES FOR \$8m TO LIST ON ASX FOR AUTISM DIAGNOSTIC**  
[BLINKLAB](#)

Blinklab says it hopes to raise up-to \$8 million at 20 cents a share in an initial public offer to list on the ASX to develop its autism and neurological disorder diagnostic. Blinklab said its test reduced autism evaluation to one or two 15-minute smartphone-based neuro-metric tests that could reduce the diagnostic age to as low as 18 months. The company said Resapp co-founder Brian Leedman was its chair, with directors Jane Morgan, Dr Richard Hopkins and Dr Anton Uvarov who was a co-inventor with Dr Henk-Jan Boele; and Westar Capital acting as lead manager to the raise.

**CONTROL BIONICS PLACES \$1m SHORTFALL; TOTAL \$2.7m**  
[CONTROL BIONICS](#)

Control Bionics says it has placed the \$1,032,396 shortfall from its non-renounceable, rights offer at 4.0 cents a share, taking the total raised to \$2.659 million. Last year, the company said its rights offer raised \$620,610, with \$1.07 million underwritten, for a total of \$1.627 million, of a hoped-for \$2.73 million (BD: Nov 29, 2023).



## **MESOBLAST: 'FDA REVASCOR HLHS RARE PAEDIATRIC DISEASE STATUS'**

### [MESOBLAST](#)

Mesoblast says it has US Food and Drug Administration rare paediatric disease (RPD) designation for Revascor, or rexlemestrocel-L, for hypoplastic left heart syndrome (HLHS).

Mesoblast said following the designation, if it received a biologics licence application for Revascor for HLHS, it could be eligible for a priority review voucher that could be "redeemed for any subsequent marketing application or ... sold ... to a third party".

## **IMUGENE DOSES 1st PHASE I VAXINIA COHORT 5 PATIENTS**

### [IMUGENE](#)

Imugene says it has dosed the first of up-to 12 patients in the fifth and final cohorts of the intra-tumoral and intravenous arms of its phase I trial of Vaxinia for cancers.

## **STARPHARMA: 'DEP-CABAZITAXEL CANCER DISEASE CONTROL'**

### [STARPHARMA HOLDINGS](#)

Starpharma says dendrimer enhanced product (DEP) cabazitaxel has a 100 percent disease control rate for adenocarcinoma and 50 percent for squamous cell carcinoma. Starpharma said the data from its phase II gastro-oesophageal trial was presented at the American Society of Clinical Oncology Gastrointestinal Cancers meeting in San Francisco from January 18 to 20, 2024.

## **VISIONEERING NATURALVUE 'FURTHER REDUCES MYOPIA PROGRESSION'**

### [VISIONEERING TECHNOLOGIES](#)

Visioneering says updated one-year data from its Naturalvue contact lens trial shows 71 percent refractive error progression and 61 percent axial length, compared to controls.

Last year, Visioneering said one-year results from its Naturalvue multifocal contact lens trial in 144 near-sighted, healthy children showed a 69 percent eye refractive error progression and 59 percent axial length compared to controls (BD: Oct 12, 2023).

## **ISLAND DOSES THIRD ISLA-101 DENGUE FEVER COHORT**

### [ISLAND PHARMACEUTICALS](#)

Island says it has dosed all eight participants in the third cohort of its single ascending dose study of ISLA-101 for dengue fever and other mosquito borne diseases.

Island said following positive results from the third cohort, the participants would return to be treated with the highest dose under fed conditions for the final dosing, with data expected in "early 2024".

## **MICROBA TO RELEASE 54.5m ESCROW SHARES**

### [MICROBA LIFE SCIENCES](#)

Microba says it will release 54,500,297 shares from voluntary escrow on January 27, 2024, and according to its most recent notice, the company had 399,820,663 shares on issue, with a further 48,031,314 shares in ASX escrow.

## **ENLITIC TO RELEASE 3.9m CDIs, 4.5m SHARES FROM ASX ESCROW**

### [ENLITIC INC](#)

Enlitic says it will release 3,925,401 Chess depository interest (CDI) options and 4,493,837 shares from ASX escrow on January 29 and February 4, 2024, respectively, but did not specify whether they were voluntary or ASX mandatory escrow.

### **PHOENIX DILUTED TO 18.3% IN CONTROL BIONICS**

#### **[CONTROL BIONICS](#)**

Sydney's Phoenix Development Fund says its 31,269,581 substantial share-holding in Control Bionics has been diluted to 18.32 percent in a rights issue (see above).

### **NIGHTINGALE DILUTED TO 12.5% OF CONTROL BIONICS**

#### **[CONTROL BIONICS](#)**

Sydney's Nightingale Partners Pty Ltd says its 21,287,595 substantial share-holding in Control Bionics has been diluted to 12.47 percent in a rights issue (see above).

### **PETER FORD DILUTED TO 11.5% OF CONTROL BIONICS**

#### **[CONTROL BIONICS](#)**

Control Bionics director Peter Ford says his substantial shareholding of 19,623,433 shares in the company was diluted to 11.50 percent in a rights issue (see above).

### **PAINCHEK APPOINTS NATALIE CLIMO CO SEC**

#### **[PAINCHEK](#)**

Painchek says it has appointed Natalie Climo from Boardroom Pty Ltd as its company secretary, effective immediately.